Besides affecting your heart and lungs, exposure to second-hand or passive smoking can also raise the chances of chronic kidney disease (CKD), which can lead to renal failure, warns a new study.
The findings showed that individuals with less or more than 3 days of exposure per week had nearly double the risk of having kidney disease when compared with participants with no second-hand cigarette exposure.
“Second-hand smoke exposure at home or in the workplace is still prevalent despite legislative actions prohibiting public smoking,” said Jung Tak Park from Yonsei University in Seoul.
“This exposure was found to be clearly related with CKD, even with less-frequent amounts of second-hand smoke exposure,” Park added.
For the study, published in the Clinical Journal of the American Society of Nephrology, the team included 131,196 non-smokers and were classified into three groups: no-exposure, less than three days per week of exposure, and three or more days per week of exposure.
Cigarette smoking and exposure to second-hand smoking have been linked with higher risks of various diseases.
According to the World Health Organisation (WHO), smoking tobacco is globally the second leading cause of heart diseases after high blood pressure.Nearly 12 per cent of cardiovascular deaths worldwide occur due to tobacco abuse and second-hand smoking.
The global health body states that of the seven million lives that tobacco claims worldwide each year, almost 900,000 are passive-smokers. (IANS)
People using e-cigarettes to quit smoking are about 95% more likely to report success than those trying to quit without help from any stop-smoking aids according to the results of a large study in England.
The research, funded by the charity Cancer Research UK and published in the journal Addiction on Thursday, analyzed success rates of several common stop-smoking methods – including e-cigarettes, nicotine replacement therapy (NRT) patches and gum, and Pfizer’s varenicline, sold as Champix in the UK.
It also adjusted for a wide range of factors that might influence success rates for quitting – such as age, social level, degree of cigarette addiction, previous attempts to quit, and whether quitting was gradual or abrupt.
Latest World Health Organization data show that smoking and other tobacco use kills more than 7 million people a year globally. Of the 1.1 billion people worldwide who smoke, around 80 percent live in poor or middle-income countries.
E-cigarettes have no tobacco, but contain nicotine-laced liquids that the user inhales in a vapor. Many big tobacco companies, including British American Tobacco, Imperial Brands and Japan Tobacco, sell e-cigarettes.
This study involved almost 19,000 people in England who had tried to quit smoking in the preceding 12 months, collected over a 12-year period from 2006 to 2018. Successful quitters were defined as those who said they were still not smoking.
As well as the 95% increased success rate for e-cigarettes, the study found that people prescribed Champix were around 82% more likely to have succeeded in stopping smoking than those who tried to quit without any aids.
“Our study adds to growing evidence that use of e-cigarettes can help smokers to quit,” said Sarah Jackson, a professor at University College London who co-led the study.
Using e-cigarettes, or ‘vaping,’ is considered by many experts to be an effective way for smokers to give up tobacco, but some in the scientific community are skeptical of their public health benefits, fearing they might normalize the idea of smoking and lead young people into the habit.
Smokers who were prescribed NRT by a medical professional were 34% more likely to quit successfully, the study found. But those buying NRT from shops were no more likely to succeed that those trying to quit without any help at all.
Experts said the results were robust and important. Peter Hajek, director of the tobacco dependence research unit at Britain’s Queen Mary University of London, said the study yielded two key findings about e-cigarettes:
“They help smokers quit at least as much as stop-smoking medications, and they are used by many more smokers. This means they generate many more quitters and do this at no cost to the NHS (National Health Service),” he said in an emailed comment. (VOA)